Forbes

On top of the current financial burdens for those trying to pay healthcare bills, medical debt can lead to undertreatment in future across a spectrum of health needs.

Medicaid work requirements start going live this summer. What early states Nebraska and Montana reveal about who how many will lose coverage—and why.

The science of a perfect espresso. How AI can help treat heart disease. NASA’s on its way back to the Moon. All that and more in this week’s edition of The Prototype.

Despite a flurry of executive actions and rhetoric about their supposed impact, thus far most favored nation policies have had little effect on prices that consumers pay.

A doctor discusses the most common issues and questions Americans may have with the FDA's approval of the new oral obesity pill Foundayo

Medicare by Choice would make available Medicare-like health plans to everyone who wants such coverage. These would then compete against private plans.

Hiring isn’t a neutral process. Why access, networks and visibility shape who gets considered — and what that means for merit.

AI tools are plentiful and being used regularly for health questions. But in the era of potential misinformation, how do we conserve TRUST?

Elevance Health’s decision to shakeup its management team is the latest sign it may take more time for the health insurance industry to rebound.

It’s widely known that weight regain is likely after discontinuing medication. But it’s the reversal of cardiovascular risk reduction that researchers found conspicuous.

The Trump administration is investigating admission policies at three medical schools to pressure them to stop building a more diverse healthcare workforce for the U.S.

Repealing the HMO Act is not on any politician’s agenda. But perhaps a better regulated, less heavily profit-oriented system of multiple payers could work in the U.S.

In this week’s edition of InnovationRx, we look the billionaire dentist, Wegovy by subscription, Kailera’s planned IPO, and more.

Targeting organ‑specific gene “switches” can reverse key markers of liver aging in mice, suggesting aging might be slowed one organ at a time rather than bodywide.